<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609047</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC 1745-ETF-BCG</org_study_id>
    <nct_id>NCT03609047</nct_id>
  </id_info>
  <brief_title>Adjuvant Palbociclib in Elderly Patients With Breast Cancer</brief_title>
  <acronym>Appalaches</acronym>
  <official_title>A Phase II Study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS With High-risk ER+/HER2- Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Association of Breast Oncologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Adjuvant Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Oncologico Italiano di Ricerca Clinica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy
      and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy
      followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this trial is to assess the efficacy of the combination of at least
      5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of
      adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III
      ER+/HER2- early breast cancer.

      This is a two-arm open-label multi-center randomized (2:1) non-comparative phase II study in
      elderly patients with stage II/III, ER+, HER2- early breast cancer for whom treatment with
      chemotherapy is indicated.

      Patients will be randomized with a 2:1 allocation rate to the following treatment arm:

        -  experimental palbociclib arm: Standard adjuvant endocrine therapy for a duration of at
           least 5 years + palbociclib for a total duration of up to 2 years.

        -  control chemotherapy arm: adjuvant chemotherapy (4 cycles of
           docetaxel/doxorubicin/epirubicin-cyclophosphamide; or of weekly paclitaxel D1, D8, and
           D15 q3w if a 3 weekly schedule is not desired), followed by standard adjuvant endocrine
           therapy for a duration of at least 5 years.

      The primary endpoint of the study is the 3-year D-RFI rate in the experimental arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">June 13, 2031</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 2:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>distant recurrence-free interval (D-RFI) rate</measure>
    <time_frame>5 years after first patient inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast cancer specific survival</measure>
    <time_frame>5 years after first patient inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years after first patient inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of permanent treatment discontinuation</measure>
    <time_frame>5 years after first patient inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Breast Cancer Stage II</condition>
  <condition>Breast Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>experimental palbociclib arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard adjuvant endocrine therapy for a duration of at least 5 years + palbociclib (one capsule 125mg QD, orally, for 21 days followed by 7 days off treatment) for a total duration of up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control chemotherapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant chemotherapy:
4 cycles docetaxel 75 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles doxorubicin 60 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles epirubicin 90 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles weekly paclitaxel 80 mg/m2 D1, D8, and D15 q3w
Followed by standard adjuvant endocrine therapy for a duration of at least 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>CDK4/6 inhibitor</description>
    <arm_group_label>experimental palbociclib arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel / cyclophosphamide</intervention_name>
    <description>Adjuvant Chemotherapy</description>
    <arm_group_label>control chemotherapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin/cyclophosphamide</intervention_name>
    <description>Adjuvant Chemotherapy</description>
    <arm_group_label>control chemotherapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin/cyclophosphamide</intervention_name>
    <description>Adjuvant Chemotherapy</description>
    <arm_group_label>control chemotherapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Adjuvant Chemotherapy</description>
    <arm_group_label>control chemotherapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women or men with stage II or stage III, early invasive breast cancer according to the
             UICC 8th edition for TNM classification

          -  Histologically confirmed Estrogen Receptor ER+ (at least 10 % of cells staining
             positive for ER), Human Epidermal Growth Factor Receptor 2 (HER-2) negative, early
             invasive breast cancer based on results of local pathology. Testing may be performed
             on diagnostic core biopsy or resection specimen.

          -  In patients with multicentric, multifocal and/or bilateral breast cancer, all
             histopathologically examined invasive tumors must meet pathologic criteria regarding
             ER and HER2-status described above.

          -  Adjuvant chemotherapy indicated and feasible according to treating physician and
             patient, based on standard clinicopathological parameters (tumor size, lymph node
             involvement, general health status, proliferation marker, patient wish) and gene
             expression profile if available.

          -  Adjuvant chemotherapy combining both anthracycline and taxanes considered not
             indicated or not feasible according to treating physician.

          -  No evidence of macroscopic distant metastases, investigated according to local
             institutional guidelines.

          -  Age ≥70 years

          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-2

          -  Patient must have undergone breast +/- axillary surgery with curative intent for the
             current malignancy ≤8 weeks before randomization.

          -  The maximum duration from last surgery to the start of the first adjuvant treatment is
             9 weeks.

          -  Patients must have sufficient resolution of any surgical side effects from the last
             surgery per physician assessment, with no active wound healing complications at the
             time of randomization.

          -  Incentive to undergo adjuvant radiation therapy when indicated per local institutional
             guidelines.

          -  Note: For patients in the palbociclib arm, radiation therapy when indicated has to
             start ≤9 weeks after last surgery. The endocrine therapy can be initiated during or
             after the radiation therapy but not later than 3 weeks after the last radiotherapy.
             Palbociclib has to start ≤3 weeks after the last radiotherapy. When radiation therapy
             is not indicated, endocrine therapy and palbociclib have to be initiated ≤9 weeks
             after last surgery.

          -  Note: For patients in the chemotherapy arm, chemotherapy has to be the first adjuvant
             treatment and has to start ≤9 weeks after the last surgery. When radiation therapy is
             indicated, this treatment has to start ≤6 weeks after the last chemotherapy
             administration. Adjuvant endocrine therapy can be initiated during or after the
             radiation therapy but not later than 3 weeks after the last radiotherapy. When
             radiation therapy is not indicated, endocrine therapy has to be initiated ≤6 weeks
             after last chemotherapy administration.

          -  Adequate organ function, evidenced by the following laboratory results within 3 weeks
             prior to inclusion:

          -  Hemoglobin ≥ 9 g/dL

          -  Absolute neutrophil count (ANC) ≥ 1500/mm3

          -  Platelet count ≥ 100,000/mm3

          -  Total bilirubin ≤ 1.5 upper limit of normal (ULN), or total bilirubin ≤ 3.0 × ULN in
             patients with documented Gilbert's Syndrome.

          -  Glomerular Filtration Rate (GFR) ≥ 30 ml/min according to Modification of Diet in
             Renal Disease (MDRD) formula or Chronic Kidney Disease - Epidemiology Collaboration
             (CKD-EPI) formula or Cockcroft and Gault formula

          -  Serum Glutamic Oxaloacetic Transaminase (Aspartate Transaminase), Serum Glutamic
             Pyruvic Transaminase (Alanine Transaminase) and alkaline phosphatase ≤ 2.5 × ULN

          -  Patients must be able and willing to swallow and retain oral medication without a
             condition that would interfere with enteric absorption.

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial

          -  Before patient registration/randomization, written informed consent must be obtained
             according to ICH/GCP, and national/local regulations.

        Exclusion Criteria:

          -  Previous history of invasive breast cancer

          -  Systemic anticancer therapy prior to the breast cancer surgery

          -  Prior therapy with any Cyclin-Dependent Kinase (CDK)4/6 inhibitor

          -  Concurrent investigational agent within 28 days of randomization

          -  Concomitant anticancer treatment with the exception of bone antiresorptive agents or
             Luteinizing Hormone-Releasing Hormone agonists in male patients treated with an
             aromatase-inhibitor

          -  History of allergic reactions attributed to compounds of chemical or biological
             composition similar to palbociclib or to chemotherapy components

          -  Medications or substances that are potent inhibitors or inducers of CYP3A isoenzymes
             within 7 days of randomization (see Chapter 5.6.3 for list of CYP3A inhibitors and
             inducers)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection (including known HIV, active hepatitis B and/or hepatitis C infection),
             symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac
             arrhythmia, or uncontrolled diabetes.

          -  Other malignancy within the last 5 years except: adequately treated non-metastatic
             non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal
             carcinoma in situ of the breast.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Wildiers, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+3227741611</phone>
    <email>1745@eortc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Cornelis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet-Hopital Universitaire ULB</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lissandra Dal Lago</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Vulsteke</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Wildiers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heilig Hartziekenhuis Lier</name>
      <address>
        <city>Lier</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelies Troch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Jerusalem</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas - Campus SL</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Els Everaert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout - Campus Sint Elisabeth</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Martens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Chakiba-Brugere</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU-Lyon - Hopital Femme Mere Enfant</name>
      <address>
        <city>Brou</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Peron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Priou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Mailliez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Venat-Bouvet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon - Hopital De La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Peron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon - Hopital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Peron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - l' Hopital de St Cloud</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne Brain</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattea Reinisch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologie Haematologie Gemeinschaftspraxis - Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Decker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Torgau</name>
      <address>
        <city>Torgau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eike Simon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Witten</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hackmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riccione Hospital Unit - Ospedale Cervesi di Cattolica</name>
      <address>
        <city>Cattolica</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rimini Hospital Unit - Ospedale Sacra Famiglia</name>
      <address>
        <city>Novafeltria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUSL Romagna - Rimini Hospital Unit - Infermi Hospital</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hikmat Abdel-Razeq</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elzbieta Senkus-Konefka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska - Curie's National Institute of Oncology - National Research Institute</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zbigniew Nowecki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Martinez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau De Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serafin Morales</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lema</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario QuironSalud</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Gonzalez Cortijo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospitales HM Sanchinarro-CIOCC</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estela Vega</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Masvidal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Salvador Bofill</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virgen del Rocio University Hospital</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Virizuela Echaburu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blackpool Teaching Hospitals NHS Foundation Trust - Blackpool Victoria Hospital-NHS Fundation Trust</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Bezecny</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust - St. Bartholomew'S Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Schmid</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>June 6, 2020</last_update_submitted>
  <last_update_submitted_qc>June 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>elderly patients</keyword>
  <keyword>CDK4/6 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

